KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Short-term Investments (2016 - 2025)

Ionis Pharmaceuticals has reported Short-term Investments over the past 17 years, most recently at $2.3 billion for Q4 2025.

  • Quarterly results put Short-term Investments at $2.3 billion for Q4 2025, up 12.14% from a year ago — trailing twelve months through Dec 2025 was $2.3 billion (up 12.14% YoY), and the annual figure for FY2025 was $2.3 billion, up 12.14%.
  • Short-term Investments for Q4 2025 was $2.3 billion at Ionis Pharmaceuticals, up from $1.9 billion in the prior quarter.
  • Over the last five years, Short-term Investments for IONS hit a ceiling of $2.3 billion in Q4 2025 and a floor of $1.2 billion in Q4 2021.
  • Median Short-term Investments over the past 5 years was $1.9 billion (2024), compared with a mean of $1.8 billion.
  • Biggest five-year swings in Short-term Investments: decreased 25.93% in 2021 and later surged 37.3% in 2022.
  • Ionis Pharmaceuticals' Short-term Investments stood at $1.2 billion in 2021, then surged by 37.3% to $1.7 billion in 2022, then grew by 12.95% to $1.9 billion in 2023, then increased by 6.4% to $2.1 billion in 2024, then increased by 12.14% to $2.3 billion in 2025.
  • The last three reported values for Short-term Investments were $2.3 billion (Q4 2025), $1.9 billion (Q3 2025), and $2.0 billion (Q2 2025) per Business Quant data.